Skip to main content

Table 1 Clinical feature of BC patients and the correlation with tCTCs and GM+CTCs

From: Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer

Clinical characteristics

tCTCs

GM+CTCs

Subgroup

n

P/Na

P

P/Nb

P

Age (years)

  

0.138

 

0.147

 ≤ 50

31

14/17

 

7/24

 

 > 50

33

21/12

 

13/20

 

Histology

  

0.475

 

0.454

 Ductal

52

29/23

 

16/36

 

 Lobular

6

2/4

 

1/5

 

 Other

6

4/2

 

3/3

 

Tumor size

  

0.946

 

0.194

 ≤ 5 cm

51

28/23

 

14/37

 

 > 5 cm

13

7/6

 

6/7

 

Grading

  

0.113

 

0.294

 I–II

35

16/19

 

9/26

 

 III

29

19/10

 

11/18

 

Lymph node invasion

  

0.414

 

0.011*

 No

14

9/5

 

0/14

 

 Yes

50

26/24

 

20/30

 

Distant metastasis

  

0.004*

 

< 0.001*

 No

46

20/26

 

7/39

 

 Yes

18

15/3

 

13/5

 

Clinical Stage

  

0.911

 

0.005*

 I–II

26

14/12

 

3/23

 

 III–IV

38

21/17

 

17/21

 

ER expression

  

0.036*

 

0.076

 –

22

16/6

 

10/12

 

 +

42

19/23

 

10/32

 

PR expression

  

0.026*

 

0.227

 –

25

18/7

 

10/15

 

 +

39

17/22

 

10/29

 

HER2 expression

  

0.469

 

0.533

 –

16

10/6

 

6/10

 

 +

48

25/23

 

14/34

 

HER2 amplification

  

0.729

 

0.917

 –

39

22/17

 

12/27

 

 +

25

13/12

 

8/17

 
  1. aP positive, N negative. The positive criterion of tCTCs is ≥ 3/5 mL
  2. bP positive, N negative. The positive criterion of GM+CTCs is ≥ 2/5 mL
  3. *P < 0.05
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us